Related Experiment Videos
Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone
The Journal of Pharmacy and Pharmacology
|May 1, 1984
Abstract:
Growth of the Dunning R3327-H prostatic adenocarcinoma, implanted in the rat, is inhibited by 6-methylene progesterone. This compound is a potent inhibitor of rat prostatic 5-alpha-reductase and in-vivo produced marked involution of the prostate. Thus the tumor requires dihydrotestosterone and not testosterone for growth.
Insights
6-methylene progesterone inhibits Dunning R3327-H prostate cancer growth in rats. This suggests the tumor relies on dihydrotestosterone, not testosterone, for growth, as the compound blocks 5-alpha-reductase.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Prostate adenocarcinoma, such as the Dunning R3327-H model, is a common cancer in male rats.
- Hormonal regulation, particularly androgens like testosterone and dihydrotestosterone, plays a critical role in prostate cancer development and progression.
Purpose of the Study:
- To investigate the effect of 6-methylene progesterone on the growth of Dunning R3327-H prostatic adenocarcinoma in rats.
- To determine the role of 5-alpha-reductase and its product, dihydrotestosterone, in the growth of this specific prostate cancer model.
Main Methods:
- Implantation of Dunning R3327-H prostatic adenocarcinoma in rats.
- Administration of 6-methylene progesterone to assess its impact on tumor growth.
- Measurement of 5-alpha-reductase activity and prostate involution.
Main Results:
- 6-methylene progesterone significantly inhibited the growth of the Dunning R3327-H prostatic adenocarcinoma.
- The compound acted as a potent inhibitor of rat prostatic 5-alpha-reductase.
- In vivo administration led to marked involution of the prostate gland.
Conclusions:
- The Dunning R3327-H prostatic adenocarcinoma requires dihydrotestosterone for its growth.
- Testosterone is not the primary androgen driving the growth of this tumor.
- 6-methylene progesterone demonstrates potential as a therapeutic agent by targeting androgen metabolism in prostate cancer.